|
TOP 5 INSIGHTS IN DRUG FORMULATION AND DELIVERY
JANUARY EDITION
|
|
|
|
|
|
Combination is no longer a niche concept in drug delivery — it’s rapidly becoming the central framework shaping how therapies are designed, regulated, and delivered. Learn why “combination” is poised to define drug delivery in 2026 and what this shift means for developers, regulators, and patients alike.
|
|
|
|
|
|
Implantable drug delivery systems promise precise, sustained, and patient-friendly treatment for chronic conditions, but challenges in anatomy, market readiness, and patient adoption mean we haven’t fully arrived—yet. Explore the current landscape, emerging opportunities, and what it will take for these therapies to become mainstream.
|
|
|
|
|
|
Nanotechnology has moved from experimental promise to a commercial drug delivery platform, reshaping how complex biologics, genetic therapies, and oncology drugs are developed, manufactured, and brought to market. Disocover the technologies, investment trends, and commercial realities driving nanotech drug delivery’s rapid rise.
|
|
|
|
|
|
In this episode of Sit and Deliver, CEO William Colton of biologics platform delivery developer Paldara Pharmaceuticals talks with videocast host Tom von Gunden about infection-combatting alternatives using hydrogel-based systems to deliver bacteriophage viral therapeutics directly to infection sites.
|
|
|
|
|
|
2025 set the stage for four drug delivery trends—digitalization, sustainability, patient centricity, and high-volume biologics—that are poised to gain momentum in 2026. See how these developments are driving innovation, improving patient outcomes, and influencing the future of drug delivery.
|
|
|
|
|
|
|
